Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial

Anna Berkenblita, i, , , Ursula A. Matulonisb, i, Joan F. Kroenerc, Bruce J. Dezubea, i, Gil N. Lamd, Luceli C. Cuasaye, Nils Brünnerf, Terence R. Jonesg, Michael H. Silvermanh and Michael A. Goldj . Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial . Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial. 2005; 99(1):50-57.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.